Abstract 5007
Background
The majority of advanced non-small cell lung cancer (NSCLC) patients who receive PD-L1/PD-1 blockade immunotherapy as a second-line treatment do not respond. These treatments might not only affect the tumor microenvironment, but also alters the systemic dynamics of immune cell populations. Thus, the role of CD4 immunity in patients undergoing PD-L1/PD-1 blockade therapy remains unclear.
Methods
Peripheral blood samples from 51 NSCLC patients were obtained previous to the initiation of the PD-L1/PD-1 blockade therapy. Baseline T cell differentiation subsets based on CD27/CD28 expression were quantified by flow cytometry and correlated with responses. Baseline CD4 and CD8 T cells from NSCLC patients were co-cultured with T cell-stimulator cell line by expressing a membrane-bound anti-CD3 single-chain antibody in A549 human lung adenocarcinoma cells line (A549-SC3 cells) and PD-1, LAG-3 and Ki67 markers were assessed by flow cytometry.
Results
In our cohort study NSCLC patients were separated in two groups by a cut-off value of 40% CD4 THD (CD27-CD28low/-) cells: “G1 cohort” patients with more than 40% THD cells, and “G2 cohort” patients with less than 40%. Objective responders were found only within the G1 cohort (P = 0.0001). Interestingly, CD4 T cells from G2 patients were remarkably impaired in proliferation after ex vivo activation with A549-SC3 cells compared to CD4 T cells from G1 patients. CD8 T cells from both G1 and G2 patients were equally impaired in proliferation. CD4 T cells from G2 donors presented a significantly higher co-expression of PD-1 and LAG-3 compared with CD4 T cell from G1 donors after stimulation. CD4 T cells from both G1 and G2 patient cohorts were proficient in cytokine expression. Moreover, the proliferative capacities of CD8 T cells were recovered during after immunotherapy but only in patients with functional proliferative CD4 immunity.
Conclusions
This study uncovers that proliferative functionality of systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. Moreover, CD4 T cells from G2 patients were not exhausted, indeed they responded to stimulation by producing cytokines although with strong co-upregulation of PD-1/LAG-3 associated with diminished proliferative capacities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Immunomodulation group-Navarrabiomed Research Center.
Funding
Asociación Española Contra el Cáncer (AECC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract